Skip to main content

Market Overview

Ultragenyx Discontinues Phase 3 GNE Myopathy Study

Ultragenyx Discontinues Phase 3 GNE Myopathy Study

Shares of Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) tumbled more than 12 percent Wednesday after the company offered a disappointing update concerning a muscle-disease drug study.

The biopharmaceutical company, which focuses on the development of novel products for rare and ultra-rare diseases, said that its Phase 3 study evaluating aceneuramic acid extended release (Ace-ER) in patients with GNE Myopathy (GNEM) failed to achieve its primary endpoint.

The study hoped to show a statistically significant difference in the upper extremity muscle strength composite score compared to placebo. The study also failed to meet its key secondary endpoints.

As such, the company will discontinue further clinical development of the Ace-ER.

JMP Securities: Limited Impact

Ace-ER's discontinuation will have a "limited" impact on Ultragenyx's valuation moving forward even though the data release was disappointing, JMP's Liisa Bayko commented in a brief research report. However, the Ace-ER program was a small contributor to the stock's overall valuation and was valued at just $3 per share based on the analyst's prior analysis.

The decision to terminate the Ace-ER program also prompted the analyst to remove the UX007 Huntington's disease (HD) program, which is valued at $7 per share as the timeline is uncertain.

"However, we are mindful that success in HD could be the biggest source of upside to our valuation as the program represents an ~$3 billion market opportunity if successful," Bayko wrote.

Bottom line, Ultragenyx's stock could see a "turning point" as soon as November with the potential approval of rhGUS for MPS7 by the FDA followed by the second approval of burosumab for XLH next April.

Shares remain Market Outperform rating with a price target lowered from $90 to $80.

Related Links:

5 Biggest Price Target Changes For Wednesday

Benzinga's Top Upgrades, Downgrades For August 23, 2017

Latest Ratings for RARE

Feb 2021SVB LeerinkMaintainsOutperform
Feb 2021BarclaysMaintainsOverweight
Feb 2021Piper SandlerMaintainsOverweight

View More Analyst Ratings for RARE
View the Latest Analyst Ratings


Related Articles (RARE)

View Comments and Join the Discussion!

Posted-In: GNE myopathy Liisa Bayko Rare Diseases Ultra Rare DiseasesAnalyst Color Price Target Top Stories Analyst Ratings Best of Benzinga

Latest Ratings

SCYXAegis CapitalMaintains40.0
ARGOBoenning & ScattergoodDowngrades
TLSAZacks Investment ResearchInitiates Coverage On7.5
TOTJP MorganUpgrades
WSOMorgan StanleyMaintains244.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at